期刊文献+

4233例住院患者医院感染现患率调查 被引量:7

Investigation on prevalence rate of nosocomial infections in 4233 hospitalized patients
原文传递
导出
摘要 目的了解医院感染的实际情况及其相关因素,有效预防与控制医院感染。方法采用横断面调查和床旁检查的方法,对某医院住院患者进行医院感染现患率调查。结果调查当日该医院有住院患者4 380例,实查4 322例,实查率为98.67%。共查出医院感染患者151例、162例次,医院感染现患率为3.49%、例次感染率为3.75%。感染部位以下呼吸道感染居首,占40.74%;医院感染高发科室分别为重症监护病房(ICU)、胸外科和神经外科。调查日住院患者抗菌药物使用率为31.54%,治疗性用药占61.17%,一联用药占80.77%。结论该医院住院患者医院感染现患率在国家规定指标范围内,抗菌药物使用基本合理,但应加强对治疗性用药患者病原学检测。 Objective To investigate the actual situation of infection and related factors in order to prevent and control hospital infections efficiently. Methods The cross sectional survey and bedside examination were used to investigate prevalence rate of hospital infection for hospitalized patients in a hospital. Results 4 322 cases were investigated of all 4 380 cases with the present investigation rate of 98. 67%. There were 151 patients with nosocomial infection( 162 case- times).The prevalence rate and case- time prevalence rate of nosocomial infections were 3. 49% and 3. 75% respectively. The lower respiratory tract ranked the first place among the infection sites,accounting for 40. 74%. The high risk departments were ICU,thoracic surgery and neurosurgery department. 31. 54% of the patients were treated with antibiotics. 61. 17% of patients were treated with antibiotics for infection treatment,of whom,80. 77% were treated with one kind of antibiotic.Conclusion The prevalence of nosocomial infection in this hospital is within the limits of the state. The uses of antibacterial are rational. While the pathogen detection should be improved.
出处 《中国消毒学杂志》 CAS 北大核心 2016年第3期258-260,共3页 Chinese Journal of Disinfection
基金 黑龙江省教育厅人文社会科学研究项目(12542146)
关键词 医院感染 现患率 横断面调查 nosocomial infection prevalence rate cross sectional survey
  • 相关文献

参考文献6

二级参考文献41

  • 1吴安华 任南 文细毛等.卫生部医院感染监测网2008年医院感染横断面调查报告.医院感染监控信息,2009,23(1):17-25.
  • 2中华人民共和国卫生部.医院感染监测规范[S].北京:中华人民共和国卫生部,2009.
  • 3Esen S, Leblebicioglu H. Prevalence of nosocomial infections at intensive care units in Turkey: a multicentre 1-day point prevalence study[J]. Scand J Infect Dis, 2004, 36 (2) : 144- 148.
  • 4Arias CA. Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J].N Engl J Med. 2009. 360(5): 439-443.
  • 5Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twentyfourth informational supplement. 2014. M100-S24 Vol 34 No. 1.
  • 6Hu F. Chen S. Xu X. et al. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai. China[J]. J Med Microbiol , 2012. 61 (Pr 1): 132- 136.
  • 7Brink AJ. Feldman C. Grolman DC. et al. Appropriate use of the carbapenems[J]. S Afr Med J. 2004. 94 (10 Pt 2): 857-861.
  • 8Chen S. Hu F. Zhang X. et al. Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatrnentj]]. J Clin Microbiol , 2011. 49( 11): 4022- 4023.
  • 9van Duin D. Kaye KS. Neuner EA. et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes[J]. Diagn Microbiol Infect Dis. 2013. 75(2): l1S-120.
  • 10Daikos GL. Tsaousi S. Tzouvelekis LS. et al. Carbapenemaseproducing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems [J]. Antimicrob Agents Chernother , 2014.58 (4): 2322-2328.

共引文献672

同被引文献55

引证文献7

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部